

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)



(10) International Publication Number
WO 2021/127480 A1

(51) International Patent Classification:

<i>C07J 63/00</i> (2006.01)	<i>A61P 35/00</i> (2006.01)
<i>A61P 9/10</i> (2006.01)	<i>A61P 37/06</i> (2006.01)
<i>A61P 17/06</i> (2006.01)	<i>A61P 27/02</i> (2006.01)
<i>A61P 19/02</i> (2006.01)	<i>A61P 25/00</i> (2006.01)
<i>A61P 25/04</i> (2006.01)	<i>A61P 25/08</i> (2006.01)
<i>A61P 25/28</i> (2006.01)	<i>A61P 25/24</i> (2006.01)
<i>A61P 27/06</i> (2006.01)	<i>A61P 25/02</i> (2006.01)
<i>A61P 27/14</i> (2006.01)	<i>A61K 31/58</i> (2006.01)
<i>A61P 29/00</i> (2006.01)	<i>A61K 31/56</i> (2006.01)

(21) International Application Number:

PCT/US2020/066073

(22) International Filing Date:

18 December 2020 (18.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/950,919	19 December 2019 (19.12.2019)	US
62/950,927	19 December 2019 (19.12.2019)	US
63/198,310	09 October 2020 (09.10.2020)	US

(71) Applicant: **REATA PHARMACEUTICALS, INC.**
[US/US]; 2801 Gateway Drive, Suite 150, Irving, TX 75063-2648 (US).

(72) Inventors: **BENDER, Christopher, F.**; 2909 Mars Drive, Garland, TX 75040 (US). **DO, Ha**; c/o Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX 75063-2648 (US). **JIANG, Xin**; 902 Mill Trail, Coppell, TX 75019 (US). **SUN, Haizhou**; c/o Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX 75063-2648 (US). **VISNICK, Melean**; 330 East Las Colinas Blvd, Unit 428, Irving, TX 75039 (US). **JANSER, Ingo**; c/o AAPharmaSyn, LLC, 3915 Research Park Drive,

Suite A1, Ann Arbor, MI 48108 (US). **SIMONS, Lloyd, J.**; c/o Kalexsyn, Inc., 4502 Campus Drive, Kalamazoo, MI 49008 (US). **SCHOSTAREZ, Heinrich, J.**; c/o Kalexsyn, Inc., 4502 Campus Drive, Kalamazoo, MI 49008 (US).

(74) Agent: **WALDECK, Andrew, R.**; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US).


(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

(54) Title: SYNTHETIC TRITERPENOID WITH NITROGEN-BASED SUBSTITUENTS AT C-17 AND METHODS OF USE THEREOF



(I)



(II)

(57) Abstract: In some aspects, the present disclosure provides compounds of the formula: (I) and (II), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer.

WO 2021/127480 A1